TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35524760

Group type: EXPERIMENTAL
Intervention: Breast nurse intervention including education, literacy material, empathetic counselling, phone call reminders, and monitoring of medication refill.
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Breast nurse intervention.
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group (no breast nurse intervention).
Number of subjects: 162
Study: 34521217

Group type: EXPERIMENTAL
Intervention: Invasive management (medical therapy + angiography and revascularization if feasible)
Number of subjects: 2553

Group type: COMPARATOR
Intervention: Conservative approach (medical therapy alone with revascularization if medical therapy failed)
Number of subjects: 2553

Group type: EXPERIMENTAL
Intervention: Invasive management
Number of subjects: 2553

Group type: EXPERIMENTAL
Intervention: Insulin-treated diabetes
Number of subjects: 2553

Group type: EXPERIMENTAL
Intervention: Non-insulin-treated diabetes
Number of subjects: 2553

Group type: COMPARATOR
Intervention: Invasive management vs conservative approach
Number of subjects: 2553
Study: 35016887

Group type: EXPERIMENTAL
Intervention: Ipilimumab plus Nivolumab
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control cohort
Number of subjects: 16
Study: 32579120

Group type: EXPERIMENTAL
Intervention: MyIDEA educational app intervention
Number of subjects: 45

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 45
Study: 34974019

Group type: EXPERIMENTAL
Intervention: Indoor dehumidification (reduced relative humidity from 75% to 45%)
Number of subjects: 36
Study: 33736740

Group type: EXPERIMENTAL
Intervention: TGT-SN
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: TGT-only
Number of subjects: 404

Group type: COMPARATOR
Intervention: Control
Number of subjects: 404
Study: 33671493

Group type: EXPERIMENTAL
Intervention: Formula containing high sn-2 palmitate (sn-2 group, n = 66)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Formula containing low sn-2 palmitate (control group, n = 67)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Breast-fed group (BF group)
Number of subjects: 199
Study: 35661659

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 40
Study: 32986682

Group type: EXPERIMENTAL
Intervention: PF-06412562 (split dose 25+20mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Standard-of-care (SoC) carbidopa/levodopa
Number of subjects: 6
Study: 36368945

Group type: EXPERIMENTAL
Intervention: 50,000 IU cholecalciferol 2wks-1
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 32667582

Group type: EXPERIMENTAL
Intervention: Short-course hyperthermic intraperitoneal chemotherapy (HIPEC) for 30 minutes
Number of subjects: 15
Study: 35272263

Group type: EXPERIMENTAL
Intervention: SMS reminders
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Meeting PA guidelines
Number of subjects: 368

Group type: COMPARATOR
Intervention: Not married
Number of subjects: 368

Group type: COMPARATOR
Intervention: Living alone
Number of subjects: 368
Study: 33507877

Group type: EXPERIMENTAL
Intervention: e-learning course with video examples
Number of subjects: 145

Group type: COMPARATOR
Intervention: attendance course with role-playing
Number of subjects: 145
Study: 33781259

Group type: EXPERIMENTAL
Intervention: Rehabilitation therapy including six levels of rehabilitation exercises
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 80
Study: 33263702

Group type: EXPERIMENTAL
Intervention: Plasma‐Lyte 148
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Slow infusion speed (333mL/h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rapid infusion speed (999mL/h)
Number of subjects: 0
Study: 35734048

Group type: EXPERIMENTAL
Intervention: Coblation extracapsular tonsillectomy
Number of subjects: 293

Group type: COMPARATOR
Intervention: Monopolar extracapsular tonsillectomy
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 293
Study: 32612104

Group type: EXPERIMENTAL
Intervention: mERAS protocol
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study: 33506955

Group type: EXPERIMENTAL
Intervention: Emicizumab prophylaxis
Number of subjects: 63

Group type: COMPARATOR
Intervention: FVIII prophylaxis
Number of subjects: 63
Study: 32458506

Group type: EXPERIMENTAL
Intervention: Home collection of semen samples
Number of subjects: 110

Group type: COMPARATOR
Intervention: Clinic collection of semen samples
Number of subjects: 110
Study: 616026133

Group type: EXPERIMENTAL
Intervention: Low-Dk contact lens (Dk=28)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-Dk contact lens (Dk=110)
Number of subjects: 10
Study: 35340225

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with aerobic exercise
Number of subjects: 60

Group type: COMPARATOR
Intervention: Exercise prescription (Control)
Number of subjects: 60
Study: 34387408

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg/d
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 33280783

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control
Number of subjects: 64
Study: 35713670

Group type: EXPERIMENTAL
Intervention: Thymosin alpha 1 (Tα1) 1.6 mg every 12 hours for the first 7 days and 1.6 mg once a day for the subsequent 7 days
Number of subjects: 508

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 508
Study: 34823120

Group type: EXPERIMENTAL
Intervention: PEGlated nanoliposome of pistachio unsaturated oils (PEGNLPUOs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32462427

Group type: EXPERIMENTAL
Intervention: Intravenous autologous bone marrow-derived MSCs
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (no MSC treatment)
Number of subjects: 31
Study: 33545758

Group type: EXPERIMENTAL
Intervention: Anti-PD-1/PD-L1 agents
Number of subjects: 3
Study: 34549251

Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous training
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 14
Study: 36448721

Group type: EXPERIMENTAL
Intervention: IPACK block added to ACB and PAI
Number of subjects: 89

Group type: COMPARATOR
Intervention: ACB and PAI only (control group)
Number of subjects: 89
Study: 33647042

Group type: EXPERIMENTAL
Intervention: Monocyte subtypes (classical, intermediate, non-classical) and total monocyte count
Number of subjects: 690
Study: 32077134

Group type: EXPERIMENTAL
Intervention: DBS home sampling
Number of subjects: 48

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 48
Study: 36477478

Group type: EXPERIMENTAL
Intervention: RHEpo (3000 IU/kg)
Number of subjects: 448

Group type: COMPARATOR
Intervention: Placebo (saline, 0.9%)
Number of subjects: 448
Study: 33755088

Group type: EXPERIMENTAL
Intervention: Low pressure (LP: 7 mmHg)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Standard pressure (SP: 12 mmHg)
Number of subjects: 127
Study: 33432852

Group type: EXPERIMENTAL
Intervention: Corrective and therapeutic exercises over 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 0
Study: 34329774

Group type: EXPERIMENTAL
Intervention: Resmetirom 80 mg daily
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 34402728

Group type: EXPERIMENTAL
Intervention: 4 mg drospirenone (DRSP)
Number of subjects: 858

Group type: COMPARATOR
Intervention: 0.075 mg desogestrel (DSG)
Number of subjects: 858
Study: 32096667

Group type: EXPERIMENTAL
Intervention: Intermittent Hypoxia-Normoxia (IHN)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Intermittent Hypoxia-Hyperoxia (IHH)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Comparison of IHN and IHH
Number of subjects: 21
Study: 34908160

Group type: EXPERIMENTAL
Intervention: Parent-Child Interactions (PCI) intervention
Number of subjects: 170

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 170
Study: 32485633

Group type: EXPERIMENTAL
Intervention: Hippotherapy (16 sessions of 30 minutes, twice a week for 8 weeks)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no hippotherapy)
Number of subjects: 33
Study: 35115352

Group type: COMPARATOR
Intervention: Usual care arm (fistula creation)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Graft placement (intervention arm)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Catheter insertion (intervention arm)
Number of subjects: 195
Study: 33710815

Group type: EXPERIMENTAL
Intervention: QL1101
Number of subjects: 535

Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 535
Study: 32392952

Group type: EXPERIMENTAL
Intervention: Minimally invasive surfactant administration (MISA)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Endotracheal intubation surfactant administration (EISA)
Number of subjects: 92
Study: 34615565

Group type: EXPERIMENTAL
Intervention: High-Intensity-Interval-Training (HIIT)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Aerobic-Endurance Exercise (AE)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Psychoeducation
Number of subjects: 51
Study: 34562262

Group type: EXPERIMENTAL
Intervention: IL-2 plus background regimen (isoniazid, rifampin, pyrazinamide, ethambutol)
Number of subjects: 1151

Group type: COMPARATOR
Intervention: Control group (background regimen of isoniazid, rifampin, pyrazinamide, ethambutol)
Number of subjects: 1151
Study: 33596857

Group type: EXPERIMENTAL
Intervention: Infographic designed by the Behavioural Insights Team (BIT)
Number of subjects: 4099

Group type: EXPERIMENTAL
Intervention: Stimuli from WHO
Number of subjects: 4099
Study: 32187462

Group type: EXPERIMENTAL
Intervention: Inclisiran (284 mg) administered by subcutaneous injection on day 1, day 90, and every 6 months thereafter for 540 days
Number of subjects: 3178

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3178

Group type: EXPERIMENTAL
Intervention: Inclisiran (284 mg)
Number of subjects: 3178
Study: 35045168

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Number of subjects: 291

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study: 33164983

Group type: COMPARATOR
Intervention: 40% pre-ASiR-V, 70% post-ASiR-V (Group A)
Number of subjects: 150

Group type: COMPARATOR
Intervention: 50% pre-ASiR-V, 70% post-ASiR-V (Group B)
Number of subjects: 150

Group type: COMPARATOR
Intervention: 60% pre-ASiR-V, 70% post-ASiR-V (Group C)
Number of subjects: 150

Group type: COMPARATOR
Intervention: 70% pre-ASiR-V, 70% post-ASiR-V (Group D)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 80% post-ASiR-V (D4 subgroup)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 90% post-ASiR-V (D5 subgroup)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 40%-90% post-ASiR-V (D0-D5 subgroups)
Number of subjects: 150
Study: 34328476

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mechanical debridement
Number of subjects: 20
Study: 35039439

Group type: EXPERIMENTAL
Intervention: TAP block with 0.4 mL/kg of 0.25% ropivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: II/IH block with 0.2 mL/kg of 0.25% ropivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: QLB with 0.4 mL/kg of 0.25% ropivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: TAP block
Number of subjects: 60

Group type: COMPARATOR
Intervention: II/IH block
Number of subjects: 60

Group type: COMPARATOR
Intervention: QLB
Number of subjects: 60
Study: 33947344

Group type: EXPERIMENTAL
Intervention: Ivermectin 200 mcg/kg/day for 5 days added to hydroxychloroquine + favipiravir + azithromycin
Number of subjects: 66

Group type: COMPARATOR
Intervention: Reference treatment (hydroxychloroquine + favipiravir + azithromycin) without ivermectin
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Ivermectin treatment
Number of subjects: 66

Group type: COMPARATOR
Intervention: Reference treatment without ivermectin
Number of subjects: 66
Study: 34521568

Group type: EXPERIMENTAL
Intervention: Vitamin D levels (intervention not specified in terms of dosage or duration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin D levels (using MR‐Egger regression)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin D levels (using WM1 method)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin D levels (using WM2 method)
Number of subjects: 0
Study: 32045565

Group type: EXPERIMENTAL
Intervention: 3D ultrasonography plus 3D-printed models
Number of subjects: 96

Group type: COMPARATOR
Intervention: Ultrasonography only
Number of subjects: 96
Study: 35295056

Group type: EXPERIMENTAL
Intervention: Orthodontic treatment with premolar extraction
Number of subjects: 98

Group type: COMPARATOR
Intervention: Orthodontic treatment without premolar extraction
Number of subjects: 98
Study: 32128561

Group type: EXPERIMENTAL
Intervention: Home pregnancy tests (HPTs) plus standard protocol (n=720)
Number of subjects: 1493

Group type: COMPARATOR
Intervention: Standard protocol alone (n=773)
Number of subjects: 1493
Study: 32985950

Group type: EXPERIMENTAL
Intervention: TTM24 (target temperature management for 24 hours)
Number of subjects: 117

Group type: COMPARATOR
Intervention: TTM48 (target temperature management for 48 hours)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: TTM24
Number of subjects: 117

Group type: COMPARATOR
Intervention: TTM48
Number of subjects: 117
Study: 32147069

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) meditation/mindfulness sessions
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard care (non-VR)
Number of subjects: 52
Study: 35578182

Group type: EXPERIMENTAL
Intervention: Fremanezumab treatment
Number of subjects: 1003
Study: 34368938

Group type: EXPERIMENTAL
Intervention: XVd (selinexor, bortezomib, dexamethasone)
Number of subjects: 0
Study: 35143273

Group type: EXPERIMENTAL
Intervention: Personalized probabilistic risk visual aid
Number of subjects: 1301

Group type: EXPERIMENTAL
Intervention: Visual aid and a video narrative
Number of subjects: 1301

Group type: COMPARATOR
Intervention: General risk information
Number of subjects: 1301
Study: 33314230

Group type: EXPERIMENTAL
Intervention: Normalized Randomized Survival Probabilities (NRSP) residuals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional goodness-of-fit (GOF) test method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonlinear test based on NRSP residuals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Graphical diagnostics with CS residuals
Number of subjects: 0
Study: 35683437

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (AT) 3 times a week for 8 weeks.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group without acupuncture.
Number of subjects: 100
Study: 35569036

Group type: EXPERIMENTAL
Intervention: BI 1015550 (18 mg twice daily)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 33079921

Group type: EXPERIMENTAL
Intervention: Topical moxifloxacin 0.5% plus CXL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical moxifloxacin 0.5%
Number of subjects: 0
Study: 32927476

Group type: EXPERIMENTAL
Intervention: 30 minutes of hypoglycemia (p-glucose < 2.9 mmol/L) followed by a euglycemic clamp
Number of subjects: 18

Group type: COMPARATOR
Intervention: Euglycemic clamp without antecedent hypoglycemia
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Antecedent hypoglycemic episodes lasting 30 minutes
Number of subjects: 18
Study: 33497862

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 2267

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2267
Study: 34129728

Group type: EXPERIMENTAL
Intervention: Lidocaine/tetracaine 7%/7% peel cream (L/T‐pC) applied 45 minutes before laser treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (emollient cream)
Number of subjects: 30
Study: 33406977

Group type: EXPERIMENTAL
Intervention: Thyroid peroxidase antibodies (TPOAb)
Number of subjects: 2507

Group type: EXPERIMENTAL
Intervention: Thyroglobulin antibodies (TgAb)
Number of subjects: 2507

Group type: EXPERIMENTAL
Intervention: Subclinical hypothyroidism (SCH)
Number of subjects: 2507

Group type: EXPERIMENTAL
Intervention: Goitre prevalence
Number of subjects: 2507

Group type: EXPERIMENTAL
Intervention: Urine iodine concentration (UIC)
Number of subjects: 2507

Group type: EXPERIMENTAL
Intervention: Thyroglobulin levels
Number of subjects: 2507
Study: 36332654

Group type: EXPERIMENTAL
Intervention: Full PopART intervention (arm A) and intervention with ART according to national guidelines (arm B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (arm C)
Number of subjects: 0
Study: 33618195

Group type: EXPERIMENTAL
Intervention: Informed Choice (self-matching)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 402
Study: 35550716

Group type: EXPERIMENTAL
Intervention: Incisional negative pressure wound therapy dressing
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard dressing
Number of subjects: 80

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 80
Study: 33849517

Group type: EXPERIMENTAL
Intervention: Interactive internet-based intervention
Number of subjects: 250

Group type: COMPARATOR
Intervention: Web-based intervention without sexual health information and interactive components (Control)
Number of subjects: 250
Study: 34845722

Group type: EXPERIMENTAL
Intervention: Healthy relationships program delivered by facilitators not employed by the high schools
Number of subjects: 1135

Group type: COMPARATOR
Intervention: Curricula-as-usual
Number of subjects: 1135
Study: 32226076

Group type: EXPERIMENTAL
Intervention: High guidance prompts
Number of subjects: 32

Group type: COMPARATOR
Intervention: Low guidance prompts
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Mobile learning module
Number of subjects: 32
Study: 36198293

Group type: EXPERIMENTAL
Intervention: Late eating
Number of subjects: 0
Study: 32912627

Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 40
Study: 36335570

Group type: EXPERIMENTAL
Intervention: Integrated microfinance/livelihood and community‐based rehabilitation (IMCBR) programme
Number of subjects: 251

Group type: COMPARATOR
Intervention: Community-based rehabilitation (CBR)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Care-as-usual
Number of subjects: 251
Study: 33559444

Group type: EXPERIMENTAL
Intervention: Epidural nerve block with 20 mL 0.375% ropivacaine 30 min before anesthesia induction
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at bilateral Neima point and Neiguan (PC 6) for 30 min before anesthesia induction
Number of subjects: 60

Group type: COMPARATOR
Intervention: General anesthesia alone (Control group)
Number of subjects: 60
Study: 32479749

Group type: EXPERIMENTAL
Intervention: Moderate-to-severe MR
Number of subjects: 1443

Group type: EXPERIMENTAL
Intervention: Moderate-to-severe AS
Number of subjects: 1443

Group type: EXPERIMENTAL
Intervention: Both moderate-to-severe MR and AS
Number of subjects: 1443

Group type: COMPARATOR
Intervention: No VHD
Number of subjects: 1443
Study: 33548080

Group type: EXPERIMENTAL
Intervention: LA-enriched diet (sunflower oil, 30-50 mL, 62-63% LA)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: ALA-enriched diet (Camelina sativa oil, 30-50 mL, 30-35% ALA)
Number of subjects: 130
Study: 33036371

Group type: EXPERIMENTAL
Intervention: ToyBox intervention
Number of subjects: 4970

Group type: EXPERIMENTAL
Intervention: Process evaluation scores from teachers and parents/caregivers
Number of subjects: 4970
Study: 32124625

Group type: EXPERIMENTAL
Intervention: Oxybutynin 5 mg tablet twice a day for 3 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Transcutaneous Tibial Nerve Stimulation (TTNS) daily for 3 months
Number of subjects: 60
Study: 33141450

Group type: EXPERIMENTAL
Intervention: Unmasked attentional blink with visual T2s
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unmasked attentional blink with auditory T2s
Number of subjects: 0
Study: 32347958

Group type: EXPERIMENTAL
Intervention: Holy Name Meditation Program
Number of subjects: 45
Study: 34865304

Group type: EXPERIMENTAL
Intervention: Metformin (PCOS-M)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo (PCOS-P)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Healthy Controls (HC)
Number of subjects: 88
Study: 33210328

Group type: EXPERIMENTAL
Intervention: Bathing between 24-48 hours after birth
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bathing between 48-72 hours after birth
Number of subjects: 80
Study: 36175648

Group type: EXPERIMENTAL
Intervention: PragmaVAC
Number of subjects: 59

Group type: COMPARATOR
Intervention: Gauze (Control)
Number of subjects: 59
Study: 34455507

Group type: EXPERIMENTAL
Intervention: Vitamin E (α-tocopherol)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Selenium
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Zinc
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 32347766

Group type: EXPERIMENTAL
Intervention: LPG stove and an 18-month supply of free LPG with behavioral reinforcements
Number of subjects: 3200

Group type: COMPARATOR
Intervention: Control arm (no LPG stove and fuel distribution)
Number of subjects: 3200
Study: 33411326

Group type: EXPERIMENTAL
Intervention: Instagram posts from the IVF community
Number of subjects: 452
Study: 34264484

Group type: EXPERIMENTAL
Intervention: Eating disorders (EDs)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: High-functioning autism spectrum disorders (HF‐ASDs)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Eating disorders (EDs) and high-functioning autism spectrum disorders (HF‐ASDs)
Number of subjects: 34
Study: 33536385

Group type: EXPERIMENTAL
Intervention: Vonoprazan-based second-line therapy
Number of subjects: 33
Study: 32976204

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Moderate Intensity Continuous Training (MICT)
Number of subjects: 42
Study: 34629186

Group type: EXPERIMENTAL
Intervention: Biosynthetic cellulose dressing (Epiprotect® S2Medical AB)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Porcine xenograft (EZ Derm®, Mölnlycke Health Care)
Number of subjects: 24